OBJECTIVE: To study whether weight reducing treatment modulates serum concentration of TNF-a a and two soluble TNF-a a receptors in obese subjects. SUBJECTS AND MEASUREMENTS: Serum concentrations of TNF-a a and two soluble receptors (sTNF-R1, sTNF-R2), plasma glucose, insulin, total cholesterol, HDL-cholesterol and triglicerides were measured in 27 obese subjects (age 48 AE 12 y, body mass index (BMI): 36 AE 6 kgam 2 ) before and after 3 months weight reducing treatment consisted of a diet & 1000 kcaladay and physical exercises. RESULTS: The mean loss of weight during 3 months' treatment was 9.3 AE 3.3 kg. The serum concentration of TNF-a a decreased after weight loss and at the same time both of the receptors (sTNF-R1,sTNF-R2) increased signi®cantly. CONCLUSION: The observed decrease of the serum concentration of TNF-a a and the increase in both TNF soluble receptors after weight reducing treatment in obese subjects, may be a counter-regulation preventing further weight loss.
Introduction
Tumor necrosis factor-a (TNF-a) is a cytokine mainly produced by macrophages in response to endotoxemia, in¯ammation and cancer. Human fat cells are a signi®cant source of endogenous TNF-a production. 1 It remains a question whether adipose tissue is a source of circulating TNF-a. 2 Some have suggested that the increased TNF-a production is restricted to adipose depots. 3 TNF-a plays a role as a mediator of insulin resistance. 4 The binding of insulin to its receptor initiates a phosphorylation cascade, which starts with autophosphorylation of the insulin receptor, IR activation of the receptor tyrosine kinase and subsequent phosphorylation of insulin receptor substrate 1 (IRS-1). Obesity predisposes to insulin resistance. 5 Studies in animal models have indicated that TNF-a expression in the adipose tissue is signi®cantly elevated in obesity. 6 TNF-a has a multiple actions in adipose tissue, which include: increased insulin resistance associated with the defects in insulin-stimulated glucose disposal; decreased activity of lipoprotein lipase (LPL) and increased hormone-sensitive lipase, preventing lipid accumulation. 7 TNF-a could be a local regulator of fat cell size, and the overproduction of TNF in adipocytes of obese animals could represent a form of adipostat designed to limit adipocyte size enlargement. 8 TNF-a exerts its effect on cell function by binding to two speci®c cell surface receptors: 9 type I, TNF-R55; and type II, TNF-R75. The extracellular portions of this membrane associated with TNF receptors have been separated from them and have been identi®ed in serum as soluble forms (sTNF-Rs). The endogenous formation of TNF-a leads to the shedding of sTNF-Rs which interfere with the binding of TNF-a to cell surface-bound TNF-Rs. The sTNF-R concentration re¯ects the activation state of the TNF-aaTNF receptor system.
Recent studies show that TNF-a is overexpressed in adipose tissue in human obesity. 1, 7 Plasma concentrations of two soluble TNF receptors were found to be elevated in obesity. 2, 10 It is still unclear whether an increased adipose production of TNF-a is re¯ected by elevated circulating TNF-a levels. Several studies have reported a lack of detectable TNF-a in the serum of obese patients 1 or no differences between obese and lean subjects. 2 This may be a consequence of the low sensitivity of the tests used. It was also suggested that TNF-a action in the insulin resistance of obesity is mediated through an autocrine-paracrine mechanism. Our previous results 11 and other studies 12 have shown increased serum levels of TNF-a in obese patients in comparison with lean subjects.
In the present study we examined whether weight reducing treatment modulates serum concentration of TNF-a and two soluble TNF-a receptors in obese subjects.
Patients and methods
The study was carried out on 27 obese subjects, 23 women and four men, aged 48.2AE 11.7 y, height 1.63 AE 0.07 m, and weight 96.9 AE 14.9 kg. Their body mass index (BMI) was 36.3 AE 5.7. All persons were diagnosed as having simple obesity without additional diseases. Patients with evidence of acute or chronic in¯ammatory diseases were excluded. The study was conducted after obtaining informed consent from all the subjects. The study was approved by the local Ethical Committee.
After measurement of the baseline values, the subjects participated in a 3 month program that included two-weekly group instruction in behavioral and dietary methods of weight control. All participants were submitted to a 1000 kcaladay balanced diet.
Each obese subject was tested twice: before and after 3 months of weight reducing treatment. The body weight and height were measured and body mass index (BMI) was calculated. The waist-to-hip ratio (WHR) was used as a measure of the pattern of fat distribution. Body composition was determined by impedance analysis using Bodystat analyzer.
Blood samples were collected in the morning, after an overnight fast. Plasma glucose, cholesterol, HDL cholesterol and triglicerides were determined by enzymatic procedure using a commercially available test kit (Cormay). LDL cholesterol was calculated using the Friedwald formula. Insulin was determined by radioimmunoassay (DPC Diagnostic Products Corporation, Los Angeles, USA).
The concentrations in blood serum of TNF-a and soluble forms of both TNF-a receptors (sTNF-R1, and sTNF-R2) were measured using a commercially available highly sensitive ELISA kits (Genzyme Diagnostics, Cambridge, USA). The detection limits were: for the TNF-a, 3.0 pgaml; sTNF-R1, less than 3.0 pgaml; and for sTNF-R2, 1.0 pgaml. The inter-assay and the intra-assay coef®cients of variation were less than 8.8%.
Data were analyzed using paired t-test. Pvalues`0.05 were considered to be statistically signi®cant. Values are presented as mean AE s.d. Multiple regression analyses were performed.
Results
The main characteristics of the patients and the effect of treatment are presented in Table 1 . The mean loss of weight during treatment was 9.3 AE 3.3 kg, and BMI decreased from 36.3 AE 5.7 at the baseline to 33.3AE 4.9 after treatment. Plasma concentration of cholesterol, LDL-cholesterol and triglycerides decreased (P`0.01, P`0.05, P`0.01 respectively); no signi®cant changes of glucose and insulin were observed ( Table 2 ). The serum concentration of TNF-a signi®cantly decreased after weight loss (Table 3) .
The most pronounced differences during weight loss were observed in the soluble TNF receptors. Both receptors sTNF-R1 and sTNF-R2 increased signi®cantly (P`0.0001), by approximately 40%.
There was a positive correlation (Table 4 ) between the serum concentration of sTNF-R1 and body weight; the sTNF-R2 correlated with body fat (% and kg). We performed a multiple regression analysis using DTNF-a, Dreceptor TNF-1 and Dreceptor TNF-2 as dependent variables. Models were ®tted to estimate the role of gender, age, WHR, loss of weight (Table 5 ) and plasma glucose, insulin and 
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Dcholesterol concentrations (Table 6 ). DTNF-a and Dreceptor TNF-2 concentrations were signi®cantly associated with loss of weight; DTNF-a showed a signi®cant association with Dcholesterol concentration. Analysis of the remaining regression coef®cients did not reveal any signi®cant associations.
Discussion
Previous studies reported the increased expression of the TNF-a mRNA in the adipose tissue of obese rodents 13 and in obese human subjects. 1, 7 Adipose tissues of obese subjects secrete increased amounts of the corresponding protein. 1 The determination of circulating cytokines is complicated by its relative instability in biological¯uids. The presence of soluble inhibitors may interfere with their measurement. TNF is rapidly cleared from the circulation, being frequently extremely low or undetectable. We observed 11 increased serum levels of TNFa in obese women in comparison with lean women. TNFa function depends of the relative concentration and clearance rate. The endogenous formation of TNF leads to the shedding of sTNF-Rs, which interfere with the binding of TNF to cell surface-bound TNF-Rs. Increase of sTNF-Rs in serum parallels or exceeds TNFa production.
Body weight reduction in obese subjects was associated with a decrease in TNFa mRNA expression in fat tissue 1 and serum. 14,15 Bastard 16 observed an increase in TNF-a mRNA levels during a very low calorie diet in subcutaneous adipose tissue in obese women. No alteration of plasma TNF-a concentrations in nine subjects was also shown after weight loss. 2 In the present study the question has been posed as to whether alterations in body mass and weight loss might lead to change in the concentrations in blood serum TNFa and both TNF soluble receptors.
In our study serum concentrations of TNFa were signi®cantly lower after weight reduction. An interesting and novel ®nding is the association of the decrease of TNFa during weight-reducing treatment with an increase in both TNF soluble receptor.
It was shown that obese subjects express more TNFR2 mRNA in fat tissue and more soluble TNFR2 in circulation relative to lean control subjects. 17, 18 TNFR1 expression and protein levels were similar in these subjects. We observed increased plasma concentrations of two soluble TNFa receptors; this discrepancy is dif®cult to explain and requires further study.
It was sugested that TNF-a could represent a form of local adipostat. 8 TNF-a participates in obesityrelated insulin resistance. Adipose tissue insulin resistance could be explained as a mechanism preventing further adipocyte lipid acumulation. Besides insulin resistance TNFa could limit adiposity through decreasing fat storage, connected with diminished expression of lipoprotein lipase (LPL). 7 The assessment of the TNFa system activity on the basis of plasma TNF receptor concentrations seems to be more reliable, because these proteins are easily detectable in plasma and remain elevated for longer periods of time. Altered expression of TNFa and its receptors after weight loss 14, 15 is probably the key to regulation of weight loss during slimming treatment. TNFa was rapidly cleared from the circulation and levels were signi®cantly lowered; the biologically stable soluble receptors, which bind and neutralize TNFa increased. The lower TNFaa sTNFRs ratio after weight reducing treatment plays a role by modulating the biological effects of TNFa and serves as a mechanism that prevents further weight loss.
Conclusion
Our results are consistent with the hypothesis that decrease of the serum concentration of TNFa and the increase in both TNF soluble receptors after weight reducing treatment in obese women may be a contraregulation preventing further weight loss. TNF-a a in obesity B Zahorska-Markiewicz et al
